NCT01486368 2023-08-04
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2 Completed
Canadian Cancer Trials Group
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Duke University
Pfizer
Pfizer